3Noh J Y, Asari T, Hamada N, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations [ J ]. Clin Endocrinol (Oxf), 2001,54 : 651-654.
4Sera N, Ashizawa K, Ando T, et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease[J]. Thyroid,2000,10:595-599.
5Gunton J E, Stiel J, Clifton-Bligh P, et al. Prevalence of positive anti-neutrophil cytoplasmic antibody(ANCA) in patients receiving anti-thyroid medication [J]. Eur J Endocrinol, 2000,142 : 587.
6Wada N, Mukai M, Kohno M, et al. Prevalence of serum anti-myeloperoxidase antineutruphil cytoplasmic antibodies(MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole [ J ]. Endocr J, 2002,49 :329-334.
7Sato H, Hattori M, Fujieda M, et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil [ J ]. J Clin Endocrinol Metab,2000,85:4270-4273.
8Winters M J, Hurley R M, Lirenman D S. ANCA-positive glomendonephritis and IgA nephropathy in a patient on propylthiouracil[J]. Pediatr Nephrol, 2002,17 : 257-260.
9Poomthavom P, Mahachoklertwattana P, Tapaneya-Olarn W, et al. Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy:report of 2 children with Graves' disease[J]. J Med Assoc Thai, 2002,85 : 295-301.
10Kawasaki Y, Suzuki T, Sike T, et al. A pediatric case of myeloperoxidase-antineutrophil cytoplasmic antibody (ANC A)-related crescentic glomerulonephritis associated with propylthiouracil treatmant for Graves' disease [ J ]. Neppon Jinzo Gakkai Shi,1998,40:612-617.
二级参考文献7
1Zhao MH, Jones SJ, Lockwood CM. Bactericidal / permeability-increasing protein (BPI) is an important antigen for antineutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol, 1995, 99: 49-56.
2Zhao MH, Lockwood CM. Azurocidin is a novel antigen for antineutrophil cytoplasmic autoantibodies (ANCA) in systemic vascutilis. Clin Exp Immunol, 1996 , 103: 397-402.
3Harper L, Cockwell P, Savage CO. Case of propylthiouracil-induced ANCA associated small vessel vasculitis. Nephrol Dial Transplant, 1998, 13: 455-458.
4Miller RM, Savige J, Nassis L, et al. Antineutrophil cytoplasmic antibody (ANCA)-positive cutaneous leucocytoclastic vasculitis associated with antithyroid therapy in Graves′ disease. Australas J Dermatil, 1998, 39: 96-99.
5Choi HK, Merkel PA, Walker AM, et al. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum, 2000, 43: 405-413.
6Kitahara T, Hiromura K, Maezawa A, et al. Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA); review of literature. Clin Nephrol, 1997, 47:336-340.
